Broker’s call: PB Fintech (Buy)

SENSEX 75,692.78

+ 1,233.25

NIFTY 23,440.80

+ 387.70

CRUDEOIL 9,234.00

 -703.00

GOLD 140,200.00

+ 1,715.00

SILVER 184,006.00

+ 4,874.00

SENSEX 75,692.78

+ 1,233.25

NIFTY 23,440.80

+ 387.70

NIFTY 23,440.80

+ 387.70

CRUDEOIL 9,234.00

 -703.00

CRUDEOIL 9,234.00

 -703.00

GOLD 140,200.00

+ 1,715.00

'; } document.getElementById("lgdv").innerHTML = htmlElements; } function numberformat(i) { return Number(parseFloat(i).toFixed(2)).toLocaleString('en', { minimumFractionDigits: 2 }) } async function gatherResponse(response) { const { headers } = response; const contentType = headers.get('content-type') || ''; if (contentType.includes('application/json')) { return await response.json() } return response.text(); } function getWidth() { if (Math.max(document.body.scrollWidth,document.documentElement.scrollWidth,document.body.offsetWidth,document.documentElement.offsetWidth,document.documentElement.clientWidth) > 991) { document.getElementById("mob").style.display = "none"; document.getElementById("lgdv").style.display = "block"; } else { document.getElementById("mob").style.display = "block"; document.getElementById("lgdv").style.display = "none"; } } getWidth(); THIS AD SUPPORTS OUR JOURNALISM. SUBSCRIBE FOR MINIMAL ADS.THIS AD SUPPORTS OUR JOURNALISM. SUBSCRIBE FOR MINIMAL ADS.

Jefferies

By KS Badri Narayanan

Updated - November 02, 2026 at 09:53 PM.

PB discussed levers to offset regulatory risks, including building non-insurance revenue, improving productivity, and aligning costs with NPVs

Target: ₹1,540

CMP: ₹928.10

PB Fintech’s September quarter revenue grew by 35 per cent y-o-y, ahead of Jefferies expectations. However, adj. EBITDA at ₹220 crore (+39 per cent y-o-y) was a miss due to higher expenses.

PB discussed levers to offset regulatory risks, including building non-insurance revenue, improving productivity, and aligning costs with NPVs. PB highlighted the risk of slower 2H growth, as GST tailwinds are behind.

Total insurance premium grew 38 per cent y-o-y, with core new health and term growing 42 per cent (o/w health +46 per cent). The renewal take rate improved by around60 bps to 7.9 per cent on account of a higher share of health renewals and the transition to a “Combined Operating” model. Management expects PB Health to reach a monthly revenue run-rate of ₹40-50 crore by Mar’26, equivalent to ₹500 crore annualised, with the business broadly around break-even.

Total expenses ex. ESOP grew by 35 per cent y-o-y vs JEFe of 29 per cent, led by higher advertising and promotion expense (+59 per cent). This led to Sep’26 qtr. adj. EBITDA missing our est. by 3 per cent. Paisabazaar sequential momentum was muted: Credit disbursal were broadly flat q-q as the company kept marketing growth subdued.

We cut FY27e PAT by 3 per cent to account for higher opex.

Our SOTP-based PT of ₹1,540 based on 26x Dec’28e EV/adj. EBITDA.

Published on November 2, 2026

THIS AD SUPPORTS OUR JOURNALISM. SUBSCRIBE FOR MINIMAL ADS. THIS AD SUPPORTS OUR JOURNALISM. SUBSCRIBE FOR MINIMAL ADS. THIS AD SUPPORTS OUR JOURNALISM. SUBSCRIBE FOR MINIMAL ADS. THIS AD SUPPORTS OUR JOURNALISM. SUBSCRIBE FOR MINIMAL ADS.Sign into Unlock benefits!

• Access 10 free stories per month
• Get notified by email for early preview to new features, discounts & offers